RCS - Eden Research plc - Small Cap Virtual Investor Conference

Eden ResearchAnnouncement

28/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231128:nRSb8894Ua&default-theme=true

RNS Number : 8894U  Eden Research plc  28 November 2023

 

Eden Research to Present at the Small Cap Virtual Investor Conference November
30, 2023

 

Company invites individual and institutional investors, as well as advisors
and analysts, to attend in person or online at VirtualInvestorConferences.com

 

Didcot, Oxfordshire, November 28, 2023 -- Eden Research plc (AIM:EDEN |
OTCQB: EDNSF), based in Oxfordshire, UK, focused on sustainable biopesticides
and plastic-free formulation technology for use in global crop protection,
animal health and consumer products industries, today announced that Sean
Smith, Chief Executive Officer, will present live at the Small Cap Virtual
Investor Conference, hosted by VirtualInvestorConferences.com, on November 30,
2023.

 

DATE: November 30, 2023

TIME: 09:30 - 10:00 ET | 14:30 - 15:00 GMT

LINK: https://bit.ly/46MMy8s (https://bit.ly/46MMy8s)

 

This will be a live, interactive online event where investors are invited to
ask the company

questions in real-time. If attendees are not able to join the event live on
the day of the

conference, an archived webcast will also be made available after the event.

 

It is recommended that online investors pre-register and run the online system
check to expedite participation and receive event updates.

 

Learn more about the event at www.virtualinvestorconferences.com
(http://www.virtualinvestorconferences.com) .

 

Recent Company Highlights

 

●    Launch of Ecovelex, Eden's third flagship sustainable crop
protection product, in collaboration with Corteva

●    Successful fundraise of £9.9 (c. $12.5) million to accelerate the
company's growth

●    Various regulatory approvals across key regions including the US and
Central Europe

●    Recent regulatory approvals have converted to 55% rise in product
sales in FY 2022.

●    Over 140 field trials run in 2023 with potential distribution
partners for an insecticide, Eden's next crop protection product

 

###

 

About Eden Research plc

Eden Research is the only UK-listed company focused on biopesticides for
sustainable agriculture. It develops and supplies innovative biopesticide
products and natural microencapsulation technologies to the global crop
protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on
natural plant defence metabolites. To date, they have been primarily used on
high-value fruits and vegetables, improving crop yields and marketability,
with equal or better performance when compared with conventional pesticides.
Eden has two products currently on the market:

 

Based on plant-derived active ingredients, Mevalone® is a foliar
biofungicide which initially targets a key disease affecting grapes and other
high-value fruit and vegetable crops.  It is a useful tool in crop defence
programmes and is aligned with the requirements of integrated pest management
programmes. It is approved for sale in a number of key countries whilst Eden
and its partners pursue regulatory clearance in new territories thereby
growing Eden's addressable market globally.

 

Cedroz™ is a bionematicide that targets free living nematodes which are
parasitic worms that affect a wide range of high-value fruit and vegetable
crops globally.  Cedroz is registered for sale on two continents and Eden's
commercial collaborator, Eastman Chemical, is pursuing registration and
commercialisation of this important new product in numerous countries
globally.

 

Eden's Sustaine® encapsulation technology is used to harness the biocidal
efficacy of naturally occurring chemicals produced by plants (terpenes) and
can also be used with both natural and synthetic compounds to enhance their
performance and ease-of-use. Sustaine microcapsules are naturally-derived,
plastic-free, biodegradable micro-spheres derived from yeast. It is one of the
only viable, proven and immediately registerable solutions to the
microplastics problem in formulations requiring encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol
EDEN. It was awarded the London Stock Exchange Green Economy Mark in January
2021, which recognises London-listed companies that derive over 50% of their
total annual revenue from products and services that contribute to the global
green economy. Eden derives 100% of its total annual revenues from sustainable
products and services.

 

For more information about Eden, please visit:  www.edenresearch.com
(http://www.edenresearch.com/) .

 

About Virtual Investor Conferences®

Virtual Investor Conferences (VIC) is the leading proprietary investor
conference series that provides an interactive forum for publicly traded
companies to seamlessly present directly to investors.

 

Providing a real-time investor engagement solution, VIC is specifically
designed to offer companies more efficient investor access.  Replicating the
components of an on-site investor conference, VIC offers companies enhanced
capabilities to connect with investors, schedule targeted one-on-one meetings
and enhance their presentations with dynamic video content. Accelerating the
next level of investor engagement, Virtual Investor Conferences delivers
leading investor communications to a global network of retail and
institutional investors.

 

 

CONTACTS:

 

Hawthorn Advisors (PR advisor to Eden Research)

eden@hawthornadvisors.com

+44 (0)20 3745 4960

 

Virtual Investor Conferences

John M. Viglotti

SVP Corporate Services, Investor Access

OTC Markets Group

(212) 220-2221

johnv@otcmarkets.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFIFSELDLTFIV